Company intelligence / Profile preview
NysnoBio
Mill Valley, California, United Statesnysnobio.com ↗
- Ownership
- Private
- Employees
- ~38
- Development stage
- Preclinical
01
Overview
NysnoBio’s lead program NB001, an AAV-based Parkin gene replacement therapy for genetically defined early-onset Parkinson’s disease, has completed preclinical proof-of-concept and safety studies. The company received funding from the Michael J. Fox Foundation to support manufacturing and IND-enabling studies. No human clinical results reported yet; first-in-human trials are anticipated following successful completion of these studies.
- Therapeutic areas
- Neurology
- Modalities
- Gene therapyAAV-based gene therapy (Adeno-associated virus vector)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Michael J. Fox Foundation for Parkinson’s Research ("MJFF") [funding partner/supporter of research and development efforts on NB001 and biomarkers].
Beyond the preview
Go deeper on NysnoBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NysnoBio.